Development of ABCC4 on various tumors and chemotherapy drugs

doi:10.3760/cma.j.issn.1673422X.2015.05.013

Abstract

YAN Jin, ZHAO Xiao-Ting, JIANG Mei, YUE Wen-Tao. Development of ABCC4 on various tumors and chemotherapy drugs[J]. Journal of International Oncology, 2015, 42(5): 367-370.

［1］ Adema AD, Floor K, Smid K, et al. Overexpression of MRP4 (ABCC4) and MRP5 (ABCC5) confer resistance to the nucleoside analogs cytarabine and troxacitabine, but not gemcitabine［J］. Springerplus， 2014, 3:732. ［2］ Russel FG, Koenderink JB, Masereeuw R. Multidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules［J］. Trends Pharmacol Sci， 2008, 29(4):200207. ［3］ Carozzo A, Diez F, Gomez N, et al. Dual Role of cAMP in the Transcriptional Regulation of Multidrug ResistanceAssociated Protein 4 (MRP4) in Pancreatic Adenocarcinoma Cell Lines［J］. PLoS One， 2015, 10(3):e120651. ［4］ Markova S M, Kroetz DL. ABCC4 is regulated by microRNA124a and microRNA506［J］. Biochem Pharmacol， 2014, 87(3):515522. ［5］ Liu YH, Di YM, Zhou Z W, et al. Multidrug resistanceassociated proteins and implications in drug development［J］. Clin Exp Pharmacol Physiol， 2010, 37(1):115120. ［6］ Lin F, Marchetti S, Pluim D, et al. Abcc4 together with abcb1 and abcg2 form a robust cooperative drug efflux system that restricts the brain entry of camptothecin analogues［J］. Clin Cancer Res， 2013, 19(8):20842095. ［7］ van de Ven R, de Groot J, Reurs AW, et al. Unimpaired immune functions in the absence of Mrp4 (Abcc4)［J］. Immunol Lett， 2009, 124(2):8187. ［8］ Qian Z, Zhu G, Tang L, et al. Whole genome gene copy number profiling of gastric cancer identifies PAK1 and KRAS gene amplification as therapy targets［J］. Genes Chromosomes Cancer， 2014, 53(11):883894. ［9］ Chen L, Gu J, Xu L, et al. RNAimediated silencing of ATPbinding cassette C4 protein inhibits cell growth in MGC803 gastric cancer cell lines［J］. Cell Mol Biol (Noisylegrand)， 2014, 60(1):15. ［10］ Wu Q, Li ZS, Li D W, et al. Relationship between the expression of hypoxiainducible factor1alpha and chemotherapy response in gastric carcinoma［J］. Zhonghua Wei Chang Wai Ke Za Zhi， 2009, 12(5):498501. ［11］ Hagmann W, Jesnowski R, Faissner R, et al. ATPbinding cassette C transporters in human pancreatic carcinoma cell lines. Upregulation in 5fluorouracilresistant cells［J］. Pancreatology， 2009, 9(12):136144. ［12］ Zhang Z, Wang J, Shen B, et al. The ABCC4 gene is a promising target for pancreatic cancer therapy［J］. Gene， 2012, 491(2):194199. ［13］ Zhao X, Guo Y, Yue W, et al. ABCC4 is required for cell proliferation and tumorigenesis in nonsmall cell lung cancer［J］. Onco Targets Ther， 2014, 7:343351. ［14］ Mayba O, Gnad F, Peyton M, et al. Integrative analysis of two cell lines derived from a nonsmalllung cancer patient—a panomics approach［J］. Pac Symp Biocomput， 2014: 7586. ［15］ Moyer AM, Sun Z, Batzler AJ, et al. Glutathione pathway genetic polymorphisms and lung cancer survival after platinumbased chemotherapy［J］. Cancer Epidemiol Biomarkers Prev， 2010, 19(3):811821. ［16］ Wang JL, Chai YH, Ji ZH, et al. Preliminary study of gene expression profile associated with risk classification of childhood patients with acute lymphoblastic leukemia［J］. Zhonghua Xue Ye Xue Za Zhi， 2011, 32(1):2933. ［17］ Copsel S, Bruzzone A, May M, et al. Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia［J］. Oncotarget， 2014, 5(19):93089321. ［18］ Montani M, Hermanns T, Muntener M, et al. Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression［J］. Virchows Arch， 2013, 462(4):437443. ［19］ Bagnoli M, Beretta GL, Gatti L, et al. Clinicopathological impact of ABCC1/MRP1 and ABCC4/MRP4 in epithelial ovarian carcinoma［J］. Biomed Res Int， 2013, 2013:143202. ［20］ Zhang YH, Wu Q, Xiao XY, et al. Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell［J］. Cancer Lett， 2010, 291(1):7682. ［21］ LopezLopez E, Ballesteros J, Pinan MA, et al. Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia［J］. Pharmacogenet Genomics， 2013, 23(2):5361. ［22］ Li F, Fridley BL, Matimba A, et al. Ecto5'nucleotidase and thiopurine cellular circulation: association with cytotoxicity［J］. Drug Metab Dispos， 2010, 38(12):23292338. ［23］ Bamba S, Tsujikawa T, Sasaki M, et al. Immunomodulators and immunosuppressants for Japanese patients with ulcerative colitis［J］. ISRN Gastroenterol， 2011, 2011:194324. ［24］ Tanaka Y, Manabe A, Fukushima H, et al. Multidrug resistance protein 4 (MRP4) polymorphisms impact the 6mercaptopurine dose tolerance during maintenance therapy in Japanese childhood acute lymphoblastic leukemia［J］. Pharmacogenomics J， 2014， In press. ［25］ Wakamatsu T, Nakahashi Y, Hachimine D, et al. The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistanceassociated proteins［J］. Int J Oncol， 2007, 31(6):14651472. ［26］ Zhang G, Wang Z, Qian F, et al. Silencing of the ABCC4 gene by RNA interference reverses multidrug resistance in human gastric cancer［J］. Oncol Rep， 2015, 33(3):11471154. ［27］ Huynh T, Norris MD, Haber M， et al. ABCC4/MRP4: a MYCNregulated transporter and potential therapeutic target in neuroblastoma［J］. Front Oncol， 2012, 2:178.

Development of ABCC4 on various tumors and chemotherapy drugs

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 0

Recommended Articles

Metrics

Comments